In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert

In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert

In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert

In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert

Sudha Shenoy About Dr. Sudha Shenoy Dr. Sudha Shenoy is currently an Associate Professor in Medicine & Cell Biology in the Division of Cardiovascular Sudha Shenoy on the web Duke University Personal Reflections and Words of Wisdom: Story From Dr. Sudha Shenoy LinkedIn Pubmed Dr. GPCR Ecosystem Unlock the Full Dr.

Sudarshan Rajagopal About Dr. Sudarshan Rajagopal Dr. Sudarshan Rajagopal obtained his B.S. in Chemistry from The University of Chicago in 1998. He subsequently enrolled in the Medical Scientist Training Program at The University of Chicago. Sudarshan Rajagopal on the web LinkedIn Website Google Scholar LinkedIn Dr.

Take our quick 5-minute audience survey to help us tailor our content to your needs. GPCR Podcast Audience Survey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player Be our Guest Listen and subscribe where you get your podcasts

Roger Sunahara About Dr. Roger Sunahara Professor Sunahara received his graduate training with Dr. In 2015 Professor Sunahara moved his laboratory to the Department of Pharmacology at the University of The Sunahara lab utilizes biochemical, biophysical and pharmacological methodologies to study GPCR-G Again, our intention is to target specific receptor subtypes. Roger Sunahara on the web UCSD Profile Google Scholar ResearchGate LinkedIn Dr.

Your tax-deductible donation supports education, collaboration, and innovation. Fueling Every Corner of the GPCR Ecosystem Every contribution directly supports the programs, tools, Happy Hours free or funding the next scholarship, your contribution makes a tangible difference. $25 Supporter Monthly donations sustain long-term programs and can be changed at any time through the donation form

Submit your partnership request with our easy-to-use online form. Join Dr. Strategic Partners Back to Partners List Submit Thanks for submitting!

Submit a problem! Get detailed information about incidents and find solutions. Join us today! Who is submitting this incident? Upload File Upload supported file (Max 15MB) Submit Thanks for submitting!

GPCR Podcast Audience Survey We are currently planning our next season and need your help. This short survey will help us understand your needs to bring you exciting and informative content. We also know that you are busy, which is why we designed this short survey that should take you 5 minutes Carrier paths, choosing research topics, switching fields, late start, failures and successes. Sam @Pharmamechanic Listen and subscribe where you get your podcasts

They're designed for scientists who want deep, data-driven discussion rather than surface-level overviews

team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player Listen and subscribe

You're engaging directly with the expert — not submitting a question to a moderator. Learn directly from world leaders in GPCR research Adriano Marchese Dmitry Veprintsev Marsha Pierce Sudarshan What came as a pleasant surprise was how didactical and well-thought-out his course was—highly recommended Also super-valuable for those of us learning how to teach pharmacology GPCR researcher Dr.

Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

His group contributed to the de-orphanization of GPR139 and GPR55, including the identification of sub-nanomolar The full arc took more than a decade and required sustained coordination across disciplines that rarely This shift places data scientists and computational biologists in a newly central role - not as support The result was a structured group management model built around four specialized subgroups, each with a senior researcher as daily supervisor - a design that reduced bottlenecks and allowed the science

and a conviction that the signaling space around a receptor is richer than single-pathway readouts suggest landscape of 90+ parallel vaccine candidates without confusing breadth of effort for probability of success This disease, for all its damage, is survivable for most people. The next one might not be. GPCR Summit 2020 announcement 01:49 Check-in with Dr. This disease, most people survive.

She subsequently joined Professor Mark Connor's laboratory at Macquarie University in Australia.

And can selectivity for one receptor subtype be engineered without redesigning the ligand from scratch 10,000-fold, and how the selectivity of the nanobody - not the ligand - is what engineers receptor subtype have been using this distinction all along: two natural ligands for the same receptor already show subtly The working model is that the nanobody anchors the conjugate at the receptor surface, positioning the Attaching a short PTH fragment to a PTHR1-selective nanobody produces a ligand selective for that subtype

Back to podcast list Strategic Partner(s) Brian Bender: Computational Probes for Orphan GPCR The GPCR superfamily Finding an endogenous agonist - when one is even known - is rarely sufficient: a large peptide or lipidated for pan-GPCR chemical probe discovery The orphan receptor problem - why endogenous agonists are not sufficient it became a forced pivot into computation at precisely the moment his modeling skills were becoming sufficient - produced an unexpected result: structural and sequence patterns connecting receptors across GPCR subfamilies

The intense physiological response—an adrenaline surge and rapid adaptation to cold—sparked his lifelong One summer he asked me: “What happens if you fall through the ice?” I said I didn't know. Suddenly he pushed me into the icy water. I remember the intense adrenaline surge. My body reacted instantly. I wasn't even cold at first. Bengtsson: And another lesson I learned from my wife: success often depends not just on knowledge but

Be sure to click Sync after making changes in a collection, so visitors can see your newest content on

Laura Duvall's lab has traced this suppression to a specific neuropeptide Y family receptor, one she to study neuropeptide Y family receptors in Aedes aegypti, with a particular focus on host seeking suppression Duvall's lab used CRISPR to mutate the receptor she had identified as important for host seeking suppression favorite includes a receptor in the female mosquito that detects a male derived signal after mating and suppresses research facility from scratch, and what day to day lab life looks like - The receptor behind mating suppression

“We had a super match… and after a month, I was already in Germany. With hundreds of subtypes and very few known ligands, the structure–function relationships remain largely now we have 400 models to start with.” – Alessandro Nicoli He explained how AlphaFold’s predictions, surprisingly computational chemistry started in 2019 during his time at the Molecular Modeling Section (MMS) under the supervision computational modeling strategies to target the antiapoptotic BCL-2 protein family, key regulators of cell survival

was trained as a biochemist and molecular biologist during my Ph.D (2005) in Spain and Belgium, and subsequently AI Summary In the podcast episode "Anything but GPCRs" featuring Dr.

applications — as well as practical guidance on handling, reconstitution, dilution, and storage to support Available across multiple spectral ranges for confocal, super-resolution, and intravital imaging. daLUXendin Hodson is a veterinary surgeon by training who pursued postdoctoral studies at the CNRS in Montpellier The company's portfolio is built around high-affinity, selective fluorescent ligands for GPCRs, supporting

field had not documented before: constitutive beta-arrestin activity at a wild-type FFA2 receptor, suppressible For Gilchrist, the result was not a surprise so much as a confirmation - if you look in the right system She also brings early industry experience from Pfizer, where her first sustained encounter with pharmacology Antibody therapeutics for GPCRs: the pipeline argument Biologics have a substantially higher success of drugging a receptor without knowing what activates it naturally, and getting therapeutic results, suggests

Receptor and the Migraine Paradox Chronic migraine sits at a peculiar crossroads in opioid pharmacology: sustained bugaboo": we still do not know reliably where many GPCRs live — which cell type, which compartment, surface academia — the cumulative load of committee service, mentorship, and representation — and argues that real support "Every person I know who studies G-protein coupled receptors will tell you — the antibodies suck. Is it on the cell surface? Is it inside the cell?

I am particularly interested in spatial signaling bias or how GPCRs can redistribute to different subcellular GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Summary Podcast Recording and Science Backgrounds Yamina and Badr discussed recording their podcast with due to the support of a theater group and a good teacher. He also explained his strategy for finding a suitable postdoc lab, which involved reaching out to labs